Scientific Posters & Publications

Clinical Studies:

Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
Scott Friedman, Arun Sanyal, Zachary Goodman, Eric Lefebvre, Mildred Gottwald, Laurent Fischer, Vlad Ratziu
Publication: Contemporary Clinical Trials 2016

CENTAUR, a Phase 2b Efficacy and Safety Study of Cenicriviroc in Adults with Non-alcoholic Steatohepatitis and Liver Fibrosis at Increased Risk of Progression to Cirrhosis
Scott Friedman, Arun Sanyal, Zachary Goodman, Eric Lefebvre, Mildred Gottwald, Laurent Fischer, Vlad Ratziu
Poster: HEP DART 2015

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants with Mild or Moderate Hepatic Impairment
E. Lefebvre, M. Gottwald, K. Lasseter, W. Chang, M. Willett, P.F. Smith, A. Somasunderarm, N.S. Utay
Publication: Clinical and Translational Science 2016

Pharmacokinetics and safety of multiple-dose cenicriviroc, a novel, oral, once-daily CCR2 and CCR5 antagonist, in adults with mild or moderate hepatic impairment
E. Lefebvre, P. Smith, M.S. Willett, K.C. Lasseter, W. Chang, M.D. Gottwald
Poster: AASLD 2014

Cenicriviroc:

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus
Melanie Thompson, Michael Saag, Edwin DeJesus, Joseph Gathe, Jay Lalezari, Alan L. Landay, Jerry Cade, Jeffrey Enejosa, Eric Lefebvre, Judith Feinberg
Publication: AIDS 2016

Cenicriviroc: A Novel Agent Targeting Immuno-Inflammatory Pathways for the Treatment of NASH with Liver Fibrosis
Eric Lefebvre
Presentation: HEP DART 2015

Oral, Once-Daily, Cenicriviroc Leads To Rapid And Potent CCR2 And CCR5 Blockade In Subjects With Advanced Liver Disease, Similar To Effects Seen In Healthy Volunteers And Hiv-1 Infected Subjects
Netanya S. Utay, Mildred Gottwald, Will Chang, Michael S. Willett, Eric Lefebvre
Poster: EASL 2015

Cenicriviroc (CVC) for the Treatment of Non-Alcoholic Steatohepatitis (NASH) in Patients with Liver Fibrosis
E. Lefebvre
Presentation: AASLD Industry Colloquium 2015

Evogliptin:

Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
J. Shirakawa, H. Fujii, K. Ohnuma, K. Sato, Yuzuru Ito, M. Kaji, E. Sakamoto, Megumi Koganei, Hajime Sasaki, Yoji Nagashima, K. Amo, K. Aoki, C. Morimoto, E. Takeda, Y. Terauchi
Publication: Diabetes, 2011

Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis
Yun-A. Jung, Yeon-Kyung Choi, Gwon-Soo Jung, Hye-Young Seo, Hye-Soon Kim, Byoung Kuk Jang, Jung-Guk Kim, In-Kyu Lee, Mi-Kyung Kim, Keun-Gyu Park
Publication: Diabetes Research and Clinical Practive, 2014

Dipeptidyl peptidase IV (DDP IV) in NASH patients
Yasemin H. Balaban, Petek Korkusuz, Halis Simsek, Hale Gokcan, Gokhan Gedikoglu, Asli Pinar, Gulsen Hascelik, Esin Asan, Erhan Hamaloglu, Gonca Tatar
Publication: Annals of Hepatology, 2007

Combinations:

Cenicriviroc and pioglitazone co-administration shows favorable pharmacokinetics and safety in healthy subjects
Mildred Gottwald, Christopher Galloway, Michael Willett, Will Chang, Eric Lefebvre
Poster: AASLD 2015

Biomarkers:

APRI and FIB-4 Index Scores Can Enrich for Subjects with Fibrotic Non-Alcoholic Steatohepatitis (NASH) in Clinical Trials: The CENTAUR Trial Data
Arun Sanyal, Vlad Ratziu, Zachary Goodman, Eric Lefebvre, Jeffrey Vest, Mildred D. Gottwald, Laurent Fischer, Scott L. Friedman
Presentation: DDW 2016

Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1-infected adults receiving cenicriviroc (CVC) over 48 weeks
M. Thompson; W. Chang; H. Jenkins, A. Flynt, M.D. Gottwald, E. Lefebvre
Poster: AASLD 2014

Pre-clinical:

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
E. Lefebvre, G. Moyle, R. Reshef, L.P. Richman, M. Thompson, F. Hong, H. Chou, T. Hashiguchi, C. Plato, D. Poulin, T. Richards, H. Yoneyama, H. Jenkins, G. Wolfgang, S. Friedman
Publication: PLOS ONE, 2016

Antifibrotic activity of dual CCR5/CCR2 antagonist cenicriviroc in a mouse model of renal fibrosis
G. Moyle, T. Richards, C. Plato, H. Jenkins, G.H.I. Wolfgang, E. Lefebvre
Poster: 20th International AIDS Conference, July 2014

Anti-Fibrotic Activity of Oral, Dual CCR2 and CCR5 Antagonist Cenicriviroc in a Mouse Model of NASH and a Rat Model of TAA-Induced Liver Fibrosis
S.L. Friedman, H. Chou, T. Hashiguchi, F. Hong, H. Jenkins, G.H.I. Wolfgang, H. Yoneyama, and E. Lefebvre
Presentation: HEP DART, December 2013

Anti-Fibrotic and Anti-Inflammatory Activity of the Dual CCR2 and CCR5 Antagonist Cenicriviroc in a Mouse Model of NASH
E. Lefebvre, T. Hashiguchi, H. Jenkins, H. Yoneyama, S.L. Friedman, G.H.I. Wolfgang
Presentation: AASLD, November 2013

Further Scientific Literature on NASH and the Role of Chemokines in Hepatic Inflammation and Fibrosis:

CCR2+ Infiltrating Monocytes Promote Acetaminophen-Induced Acute Liver Injury – Therapeutic Implications Of Inhibiting CCR2 And CCL2
O. Krenkel, J.C. Mossanen, C. Ergen, F. Heymann, E. Lefebvre, D. Eulberg, C. Trautwein, F. Tacke
Abstract: EASL 2015

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases (AASLD) - Food and Drug Administration (FDA) joint workshop
Arun J. Sanyal MBBS, MD, Scott L. Friedman MD, Arthur J. McCullough MD and Lara Dimick MD
Publication: Hepatology 2014

Roles for Chemokines in Liver Disease
Marra & Tacke
Publication: Gastroenterology 2014

Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (MCP-1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice
Baeck et al
Publication: Hepatology 2014

CCR2 & CD44 Promote Inflammatory Cell Recruitment during Fatty Liver Formation
Egan et al
Publication: PLOS ONE 2013

Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
Miura et al.
Publication: American Journal of Physiology 2012

Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases
Qihong Zhao
Publication: Journal of Leukocyte Biology 2010

Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice
Mitchell et al.
Publication: American Journal of Pathology 2009

CCR1 and CCR5 Promote Hepatic Fibrosis in Mice
Seki et al.
Publication: The Journal of Clinical Investigation 2009

CCR2 Promotes Hepatic Fibrosis in Mice
Seki et al.
Publication: Hepatology 2009